Abstract Submission The main text of the abstract has a 250 words limit. The title,…

Patient and Public Involvement and Engagement Award 2026 – Deadline extended
PPIE Award:
Recognising patient and public involvement in cell and gene therapy development
Introduction
Including patient and public involvement in research studies and the development process of new therapies is recognised as good practice. The National institute for Health Research (NIHR) and the Health Research Authority (HRA) expect evidence of patient and/or public involvement in funding applications and research submissions. The HRA indicates that research teams who involve patients and the public deliver programmes that are:
More relevant to participants
Better designed to be more acceptable to participants
Have clearer information for participants
Provide a better experience of research
Are better able to communicate results to participants
Purpose:
Recognise and celebrate PPIE achievements made by those working in the field
Identify excellent practice and case studies to disseminate to other developers
Award presented during the annual BSGCT conference: £500 Award and Trophy
Winners will be highlighted on BSGCT Website as a “Case Study”.
Eligibility:
Candidates self-nominate for the award
The nomination proposal must be made in the application form included below, provide contact details, and include a brief justification addressing the judging criteria
Awardees must be available to receive the award at the next BSGCT Annual Conference.
Judging Criteria:
Motivation for the interaction
Nature of the PPIE activity (ie Survey, focus group & who was involved)
Short statements on whether this was a rewarding experience from the point of view of The team developing the therapy, The patient(s) involved
Impact of the interaction? ( ie Has it resulted in changes to approach or design of future studies involving patients?)
Closing date for nominations extended to 23 February 2026.
Awarding Decisions:
Panel review comprising BSGCT Board & ATMP Engage/Patient and public representatives. Panel decisions will be final.
